tiprankstipranks
Analyst Profile
Followed by 130 other investors
.
Tyler Van Buren

Tyler Van Buren

Cowen & Co.
Wall Street Analyst
Ranked #6,271 out of 8,014 Analysts on TipRanks (#16,889 out of 21,455 overall experts)

Success Rate

44%
135 out of 306 Profitable Transactions

Average Return

-1.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Tyler Van Buren's ratings since 2015 and opened each position for the duration of 1 Year:
44.12% of your transactions would have been profitable with an average return of -1.1%

Stock Rating Distribution

434Ratings
82.72% Buy
16.59% Hold
0.69% Sell
Distribution of Tyler Van Buren's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
BioCryst Pharmaceuticals
(BCRX)
Rating Type:Buy
Dates:Sep 30, 2020 - Sep 30, 2021
Gain:318.30%
The most profitable rating made by Tyler Van Buren

Tyler Van Buren's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
NeuBase Therapeutics
Buy
Reiterated
$15.00
(1160.50% Upside)
0%
-62.10%
2
Ocular Therapeutix
Buy
Reiterated
100%
+63.40%
1
IVERIC bio
Hold
Downgraded
$6.00
(-54.99% Downside)
0%
-70.70%
6
GlaxoSmithKline
Hold
Reiterated
$49.00
(41.58% Upside)
0.00%
1
Teva Pharmaceutical
Hold
Downgraded
$30.00
(167.98% Upside)
0.00%
1
Innoviva
Buy
Reiterated
$16.00
(10.57% Upside)
100%
+16.71%
12
Alder Biopharmaceuticals
Buy
Initiated
100%
+49.30%
1
Neos Therapeutics
Buy
Reiterated
33%
-25.50%
3
Aerie Pharma
Buy
Reiterated
$100.00
(794.45% Upside)
50%
-2.15%
4
Amneal Pharmaceuticals
Hold
Reiterated
$16.00
(449.83% Upside)
0.00%
6
List of latest recommendations made by Tyler Van Buren. Click to expand and see Tyler Van Buren's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More